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Androgens Upregulate Cdc25C Protein by Inhibiting Its
Proteasomal and Lysosomal Degradation Pathways
Yu-Wei Chou1., Li Zhang1,2., Sakthivel Muniyan1, Humera Ahmad1, Satyendra Kumar1, Syed
Mahfuzul Alam1, Ming-Fong Lin1,3,4,5*
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Abstract
Cdc25C is a cell cycle protein of the dual specificity phosphatase family essential for activating the cdk1/Cyclin B1 complex
in cells entering into mitosis. Since altered cell cycle is a hallmark of human cancers, we investigated androgen regulation of
Cdc25C protein in human prostate cancer (PCa) cells, including androgen-sensitive (AS) LNCaP C-33 cells and androgenindependent (AI) LNCaP C-81 as well as PC-3 cells. In the regular culture condition containing fetal bovine serum (FBS),
Cdc25C protein levels were similar in these PCa cells. In a steroid-reduced condition, Cdc25C protein was greatly decreased
in AS C-33 cells but not AI C-81 or PC-3 cells. In androgen-treated C-33 cells, the Cdc25C protein level was greatly elevated,
following a dose- and a time-dependent manner, correlating with increased cell proliferation. This androgen effect was
blocked by Casodex, an androgen receptor blocker. Nevertheless, epidermal growth factor (EGF), a growth stimulator of PCa
cells, could only increase Cdc25C protein level by about 1.5-fold. Altered expression of Cdc25C in C-33 cells and PC-3 cells by
cDNA and/or shRNA transfection is associated with the corresponding changes of cell growth and Cyclin B1 protein level.
Actinomycin D and cycloheximide could only partially block androgen-induced Cdc25C protein level. Treatments with both
proteasomal and lysosomal inhibitors resulted in elevated Cdc25C protein levels. Immunoprecipitation revealed that
androgens reduced the ubiquitination of Cdc25C proteins. These results show for the first time that Cdc25C protein plays a
role in regulating PCa cell growth, and androgen treatments, but not EGF, greatly increase Cdc25C protein levels in AS PCa
cells, which is in part by decreasing its degradation. These results can lead to advanced PCa therapy via up-regulating the
degradation pathways of Cdc25C protein.
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G2-phases and activates Cdc2/cyclin B at mitotic entry [10].
Results of several studies show the importance of Cdc25C in cell
cycle regulation during the G2-to-mitosis transition
[12,13,14,15,16,17] and in response to DNA damage and
replicational stress [18,19,20]. Upon DNA damage, cells will
arrest the cell cycle and induce the transcription of genes needed
for DNA repair. Cdc25C can be negatively regulated by Ser-216
phosphorylation for cytoplasmic sequestration [19,21]. Cdc25C
activity can also be inhibited via phosphorylation by checkpoint
kinases Chk1 and Chk2 when there is a DNA damage, which will
prevent cyclin B/cdk1 activation [22]. Activated Chk kinases
phosphorylate Cdc25C at Ser-216, blocking the activation of cdk1
and subsequent transition into the M phase [23]. Additionally,
Cdc25C can be inactivated by Wee1 and Myt1 kinases in the
cyclin B/cdk1 complex [24].
Due to the importance of Cdc25 members in cell cycle
regulation, this group of enzymes has received much attention.
However, the majority of studies on Cdc25 members thus far have
been focused on investigating the phosphorylation and consequent

Introduction
Cell cycle progression is controlled by the sequential activation
of cyclin-dependent kinase (CDK) whose activities are tightly
regulated by cyclins, CDK inhibitor, and a variety of other
proteins [1,2]. Cell division cycle (Cdc) 25 proteins are highly
conserved dual specificity phosphatases that activate CDK
complexes, which in turn regulate the progression through
different phases of cell cycle [3]. Cdc25 proteins are encoded by
a multigene family, consisting of three isoforms with different
molecular weights: Cdc25A, Cdc25B and Cdc25C [4,5,6].
Although it was initially proposed that each Cdc25 has a specific
role in a particular stage of the cell cycle, including results from
mutant mice experiments [7,8,9]; current results indicate that
these Cdc25 proteins have overlapping functions [3].
Cdc25A is involved in mitosis and the checkpoint signaling
pathway [10], and also functions as an oncogenic protein with
overexpression in several human malignancies including liver,
breast and ovarian cancers [11]. Cdc25B plays a role in S- and
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80 as C-81 [26,41]. LNCaP C-33 cells express functional
androgen receptor (AR), are androgen-sensitive (AS) cells, and
cell growth is greatly decreased in the absence of androgen.
Despite C-81 cells expressing a similar level of functional AR to C33 cells, they are androgen-independent (AI), -responsive cells
[26,41]. Thus, C-81 cells grow very well in the absence of
androgen with a low degree of androgen stimulation, mimicking
advanced clinical PCa [26,41].
For DHT treatments, LNCaP C-33 and C-81 cells were steroidstarved for 48 hr in a steroid-reduced (SR) medium, i.e., phenol
red-free RPMI 1640 medium containing 5% charcoal/dextrantreated, heat-inactivated certified FBS, 2 mM glutamine and
50 mg/mL gentamicin. Cells were then exposed to 10 nM DHT
for a time period specified in each experiment.

subcellular localization and cell cycle regulation. Very little data is
available regarding the activator of Cdc25 members, especially
Cdc25C and its biological significance relating to specific
carcinogenesis [25].
In this study, we investigated the regulation of protein tyrosine
phosphatase (PTP) proteins by androgens in prostate cancer (PCa)
cells because androgens play a critical role in diverse activities of
prostate cells including normal development, differentiation and
pathogenesis. Androgen sensitivity is also a hallmark of PCa. To
study androgen effect on PCa cell proliferation, we analyzed the
protein level of cellular prostatic acid phosphatase (cPAcP), an
authentic PTP, as a marker for androgen action; because cPAcP
functions as a negative growth regulator by dephosphorylating
ErbB-2 tyrosine phosphorylation [26,27,28]. In growth-stimulated
PCa cells by both androgen and EGF, the cPAcP level is decreased
[29,30]. Our data clearly showed that the Cdc25C protein level is
positively correlated with androgen status and plays a role in
regulating PCa cell proliferation. In androgen-treated cells, cPAcP
is decreased and Cdc25C is up-regulated, leading to growth
stimulation. Despite the fact that there are many studies on
Cdc25C, to the best of our knowledge, this is the first report that
clearly showed Cdc25C protein is up-regulated by androgens, but
not by EGF, and plays a critical role in regulating both basal and
androgen-stimulated PCa cell growth. Furthermore, androgens
up-regulate Cdc25C protein levels at least in part by inhibiting its
degradation pathways, which lead to PCa cell proliferation. Our
results may lead to the development of effective therapy toward
advanced castration-resistant PCa via down-regulating Cdc25C
protein levels.

Cdc25C cDNA and shRNA plasmids transfection and cell
growth determination
For Cdc25C cDNA and shRNA plasmid transfection, LNCaP
C-33 and PC-3 cells were plated in regular medium at a density of
1.26104 and 16104 cells/cm2, respectively, for 72 hr and then
transfected with Cdc25C cDNA or shRNA. Control cells were
transfected with the vector alone. Five hours after transfection, all
transfected cells were fed with RPMI medium with 10% FBS for
24 hr. In cDNA transfection experiments, both cDNA- and vector
alone-transfected C-33 cells were maintained in fresh regular
medium for 2 days and then harvested for cell number counting.
In shRNA transfection experiments, shRNA- and vector alonetransfected C-33 cells were transferred to SR medium for 2 days
and then treated with or without 10 nM DHT for 2 days prior to
cell number counting; while shRNA-transfected PC-3 cells were
maintained in regular medium for 2 days before cell counting. Cell
numbers were counted in a Nexcelom Biosciences CellometerTM
Auto T4 Image-based cell counter (Nexcelom Biosciences,
Lawrence, MA, USA) [27]. Total cell lysate proteins were
analyzed by western blotting for Cdc25A, Cdc25B, Cdc25C,
cyclin B1 and cyclin D1 protein levels. b-actin was used as a
loading control.

Materials and Methods
Materials
Fetal bovine serum (FBS), RPMI 1640 culture medium,
glutamine and gentamicin were purchased from Invitrogen
(Carlsbad, CA, USA). Charcoal/dextran-treated, certified FBS,
anti-b-actin antibody (Ab) and 5a-dihydrotestosterone (DHT)
were obtained from Sigma (St. Louis, MO, USA). Polyclonal Ab to
Cdc25C protein (Sc327) was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit anti-PAcP
ATM-3 antisera were obtained as described previously [29]. The
Cdc25C shRNA plasmid and control plasmid, and the horseradish
peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulin G (IgG) were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The Cdc25C cDNA plasmid was
purchased from OriGene Technologies, Inc. (Rockville, MD,
USA). All other chemicals were as described previously
[26,31,32,33].

Immunoblotting and immunoprecipitation
For immunoblotting, subconfluent cells were harvested by
scraping. After centrifugation for 10 min at 1,000x g at 4uC, the
pelleted cells were rinsed with ice-cold 20 mM HEPES-buffered
saline, pH 7.0, and then lysed in ice-cold cell lysis buffer
containing protease and phosphatase inhibitors. The detailed
protocols for immunoblotting were described previously
[26,27,31]. The intensity of hybridization band was semiquantified
by densitometric analyses of autoradiograms with different
exposure time periods using ImageJ.exe program (http://rsb.
info.nih.gov/). To calculate the relative protein level, each
densitometer reading was first normalized to that of the
corresponding b-actin protein. This ratio was further compared
to that of control cells, which was designated as 1.0.
For immunoprecipitation, cells were harvested and washed with
ice-cold 20 mM HEPES-buffered saline, pH 7.0, pelleted by
centrifugation, and lysed on ice for 20 minutes with lysis buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, protease inhibitor cocktail). Ab to Cdc25C protein (3 mg) was
incubated with Protein A-Sepharose beads (50 mL of 10%
suspension) in 500 mL of lysis buffer for 1 hour at 4uC. Cell
lysates (0.3 mg) were incubated with Ab-coated Protein ASepharose beads in a volume of 500 mL at 4uC for 2 hr. Beads
were washed three times (1 mL each) with ice-cold lysis buffer.
Immunoprecipitated proteins were eluted by heating at 95uC for 5
minutes in Laemmli sample buffer (50 mM Tris HCl, pH 6.8, 2%

Cell culture
Human prostate carcinoma cell lines including LNCaP cells
[34], MDA PCa2b cells [35], PC-3 cells [36], DU 145 cells [37]
and VCaP cells [38] were originally purchased from the American
Type Culture Collection (Rockville, MD, USA). LNCaP, PC-3
and DU 145 cells were routinely maintained in the regular culture
medium, i.e., phenol red-positive RPMI 1640 medium supplemented with 5% FBS, 2 mM glutamine and 50 mg/mL gentamicin [31]. MDA PCa2b cells were cultured in BRFF-HPC1
medium containing 20% FBS, 2 mM glutamine and 50 mg/mL
gentamicin [27,39]; while VCaP cells were cultured in DMEM
containing 10% FBS, 2 mM glutamine, 50 mg/mL gentamicin
and 10 nM DHT [40]. Cells were split once per week, which was
defined as one passage. LNCaP cells with passage numbers less
than 33 were designated as C-33, those with numbers greater than
PLOS ONE | www.plosone.org
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SDS (v/v), 0.001% bromophenol blue, 10% glycerol (v/v),
100 mM dithioerythritol), and then subjected to immunoblot
analyses.

Flow cytometry
For analyzing DHT effect on PCa cell cycle, AS C-33 cells were
seeded at a density of 26104 cells/cm2 in regular medium for 3
days followed by maintaining in SR medium for 2 days. Cells were
then treated with 10 nM DHT or solvent alone. For a time period
specified in each experiment, cells were trypsinized, harvested and
washed twice by Hank’s balanced salt solution. Cells were treated
with 70% ethanol at 4uC for 1 hr, washed with PBS and spun
down by centrifugation. The DNA in ethanol-fixed cells was
stained by the propidium iodide (PI) staining reagent at 4uC for 30
minutes. The PI staining reagent was prepared in PBS, pH 7.4,
containing 0.1% Triton X-100, 0.1 mM EDTA disodium salt,
0.05 mg/ml RNaseA (50 U/mg), and 50 mg/ml PI [42]. The
determination of cell cycle distribution was carried out using a
Becton-Dickinson fluorescence-activated cell sorter (FACSCalibur,
Becton Dickinson, San Jose, CA, USA) at the UNMC Flow
Cytometry Core Facility.

Statistical Analysis
Each set of experiments was performed in duplicate or
triplicate, specified in each figure legend or experimental design,
repeated at least 2–3 times and the mean and standard error or
standard deviation values of experimental results were calculated.
Paired two-tailed Student’s t-tests were used for comparison
between each group. p,0.05 was considered statistically significant [28,43].

Figure 1. Expression profiling of protein phosphatases and cell
cycle proteins in different PCa cells. LNCaP C-33, C-81 and PC-3
PCa cells were plated at a density of 86103, 66103 and 4.86103 cells/
cm2, respectively, in duplicates for 3 days in regular medium. (Left FBS
panel, lanes #1–3) Cells were replaced with fresh regular medium for
24 hr and then harvested. (Right SR panel, lanes #4–6) All three PCa
cells were then steroid-starved for 48 hr in a steroid-reduced (SR)
medium and then harvested. Total cell lysate proteins were analyzed for
cPAcP, SHP1, SHP2, Cdc25A, Cdc25B, Cdc25C, Cyclin B1 and Cyclin D1.
Cdc25C spliced forms were observed upon long exposure of films
(lower panel of Cdc25C). b-actin was analyzed and used as a loading
control.
doi:10.1371/journal.pone.0061934.g001

Results
Expression profiles of protein tyrosine phosphatases in
different prostate cancer cells
We conducted analyses on the protein profiling of PTPs in PCa
cells. We first validated the cell model system, including AS
LNCaP C-33 and AI LNCaP C-81 as well as PC-3 cells, by
analyzing the status of cPAcP because cPAcP exhibits the PTP
activity and its protein level inversely correlates with PCa cell
growth [26,29,30,44]. In regular medium containing FBS, cPAcP
is expressed in slow growing C-33 cells, while low or no expression
in rapidly growing AI C-81 and PC-3 cells (Fig. 1, FBS, lanes #1–
3), as we reported previously [26]. In those cells, as shown in Fig. 1
(FBS, lanes #1–3), SHP-1 and SHP-2 protein levels were very
similar, except PC-3 cells had a low level of SHP-1 protein [28].
Among three Cdc25 family members, the protein level of Cdc25A
was very similar among these three cell lines; while Cdc25B is
higher in PC-3 cells than in C-33 and C-81 cells, and Cdc25C is
slightly higher in C-81 cells than in C-33 and PC-3 cells (Fig. 1,
lanes #1–3). We also analyzed the spliced forms of Cdc25C
protein upon long term exposure of x-ray films to ECL reagentstreated blots. While there are some minor differences in the spliced
form proteins of Cdc25C among three cell lines; similar species of
spliced form proteins were detected. We semiquantified the
protein level of the mature form Cdc25C protein in the pair of
LNCaP cells by densitometric analyses on autoradiograms
followed by calculating the ratio. The ratio of Cdc25C protein
level in AI C-81 cells was about 1.2-fold of that in AS C-33 cells.
Interestingly, while all cells had a similar level of Cyclin D1
protein; the Cyclin B1 protein level in C-81 cells was higher than
in C-33 and PC-3 cells (Fig. 1, FBS panel, lanes #1–3).
We examined the effect of SR media on the phosphatase
profiling. The SR media contain the phenol red-free medium with
PLOS ONE | www.plosone.org

charcoal/dextran-treated, certified FBS in which many small
molecules including steroids and growth factors were removed. In
SR condition, C-33 cell growth was greatly decreased and cPAcP
was elevated, higher than that in regular medium (Fig. 1, lane #4
vs. #1) [28]. In those three cell lines in SR media, while the
protein levels of SHP-1 and SHP-2 remained essentially the same
as that seen in regular medium (Fig. 1, FBS panel vs. SR panel);
the protein levels of Cdc25 A and B were slightly decreased in AS
LNCaP C-33 cells, lower than in AI C-81 and PC-3 cells (Fig. 1).
The ratio of intensities of hybridization bands of Cdc25 A and B in
C-33 cells were about 0.6- and 0.4-fold of that in AI C-81 cells,
respectively, by densitometric analyses on western blots and
followed by normalizing to that in AI C-81 cells. Unexpectedly, in
SR conditions, the mature form Cdc25C protein level was greatly
diminished in C-33 cells and could be detected only upon
prolonged exposure of films (Fig. 1, Long exposure, lane #4).
Among spliced form proteins, the 50 kDa spliced form protein of
Cdc25C decreased in all three cell lines under SR condition (Fig. 1,
Long exposure, lanes #4–6). In SR media, Cyclin B1 and D1
protein levels were also greatly decreased in AS C-33 cell,
indicating a slow cell growth in SR media; while only Cyclin B1
slightly decreased in AI C-81 and PC-3 cells (Fig. 1, SR panel).
The data collectively indicate that among three Cdc25 members,
Cdc25C protein is the most sensitive member to the SR condition.
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signaling transduction, we analyzed EGF effect on Cdc25C
protein levels with 1 hr treatment. Our results revealed that 1 hr
EGF treatment had no significant effect on Cdc25C protein level
in C-33 cells (data not shown). The data together clearly show that
Cdc25C is the most sensitive Cdc25 member to androgens in AS
PCa cells in which AR is required for this effect. Furthermore,
DHT, but not EGF, can greatly increase Cdc25C protein level;
while both factors can cause a decrease of cPAcP protein level and
stimulate LNCaP C-33 cell proliferation (Fig. 2D) [29].

Effects of androgens on Cdc25C protein level in PCa cells
Since Cdc25C protein exhibits the most distinct sensitivity to
SR conditions among three Cdc25 members (Fig. 1, lane #4), and
also since SR media contain reduced amounts of steroids and
growth factors, we first examined DHT dosage effect on Cdc25C
protein level in AS LNCaP C-33 cells, and AI LNCaP C-81 cells
were used as controls. Our results showed that Cdc25C protein
level was greatly elevated in C-33 cells by 10 nM and 100 nM
DHT treatments for 48 hr, following a dose-dependent manner
(data not shown). Cyclin B1 and D1 were also elevated, following
the same fashion in those DHT-treated cells. Conversely, cPAcP
protein levels decreased with increasing concentrations of DHT in
C-33 cells (data not shown) as reported previously [26,29,31]. On
the contrary, C-81 cells had high endogenous levels of Cdc25C
protein in the absence of DHT, therefore, the DHT effect on
Cdc25C protein levels in these cells was greatly reduced (data not
shown). Similarly, DHT had only minor effects on Cyclin B1 and
D1 proteins of high basal levels in C-81 cells, and in these C-81
cells, cPAcP protein level was very low and could be seen only
upon prolonged exposure of films (data not shown).
Since 10 nM DHT had the optimal effect on the Cdc25C
protein level, it was used in subsequent experiments. Kinetic
analyses showed that 10 nM DHT could greatly increase the
Cdc25C protein level in C-33 cells upon 24 hr and 48 hr
treatments (Fig. 2A, lane #2 vs. #1 and lane #6 vs. #5). In
comparison, DHT has much less effect on Cdc25B protein than
on Cdc25C (Fig. 2A). In those same DHT-treated C-33 cells,
Cyclin B1 and D1 levels were elevated; while cPAcP was
decreased in DHT-treated cells (Fig. 2A). In comparison, DHT
effects on these protein levels in AI C-81 cells were greatly
decreased (Fig. 2A, lane #4 vs. #3 and #8 vs. #7). Thus, DHT
effect on the Cdc25C protein level in C-33 cells followed a kinetic
response.
We analyzed if AR activity is required in DHT-increased
Cdc25C protein. LNCaP C-33 and VCaP cells, another androgen-responsive PCa cell line, were treated with 10 nM DHT in the
presence or absence of 10 mM Casodex, an AR blocker in clinical
usage. When these two AS PCa cells were treated concurrently
with Casodex, DHT effect on Cdc25C and/or cPAcP protein
levels were blocked (Figs. 2B & 2C, lane #4 vs. #3). Casodex
could also prevent DHT from increasing the protein levels of
Cyclin B1 and Cyclin D1 (Figs. 2B & 2C). Consistently, DHT has
no effect on Cdc25A with a low degree of effects on Cdc25B
protein level in C-33 cells (Fig. 2B). As a control, Casodex blocked
DHT-induced PSA protein levels, an androgen-regulated protein
(Figs. 2B & 2C). Thus, despite that there were differential effects
on AR protein levels in these two cells; a functional AR is
apparently required in DHT-induced Cdc25C protein level.
Since EGF can stimulate LNCaP cell proliferation with a
decrease of cPAcP activity [29], and also since the charcoal-treated
FBS in SR medium also contain reduced amounts of small
molecules including EGF other than steroids [29], we examined if
EGF treatment could also increase Cdc25C protein levels.
Unexpectedly, while Cdc25C and Cyclin B1 protein levels were
greatly elevated in 24 hr DHT-treated C-33 cells; these two
proteins were increased by only up to 2-fold in EGF-treated C-33
cells upon 24 hr-treatment (Fig. 2D). As controls, in those same
cells, EGF treatment greatly cross-activated ErbB-2 tyrosine
phosphorylation as indicated by great increase of pY877 level,
and DHT treatment could activate both AR as shown by S81
phosphorylation and ErbB-2 by pY877 phosphorylation, although
to a lesser degree on activating ErbB-2 than EGF (Fig 2D).
Furthermore, upon both DHT and EGF treatments, cPAcP levels
were decreased (Fig. 2D). Since EGF exhibits a rapid effect on
PLOS ONE | www.plosone.org

Effect of Cdc25C protein expression on the growth of
PCa cells
We investigated the biological significance of elevated Cdc25C
by DHT on cell growth by performing cell cycle analysis using
flow cytometry. In DHT-treated C-33 cells, Cdc25C protein level
was elevated (Fig. 2); concurrently, the percentage of cell
population in the S phase of cell cycle was increased (Fig. 3). In
DHT-treated C-33 cells, the population of cells in the S phase was
increased by approximately 50%; i.e., from 28% to 43% at 24 hr
(Figs. 3A & 3B) and from 19% to 29% at 48 hr treatment (Figs. 3C
& 3D). Thus, Cdc25C protein level is associated with DHTstimulated cell proliferation, and concurrently, Cyclin B1 and D1
protein levels were also elevated (Fig. 2).
We determined the role of Cdc25C in the growth of PCa cells.
C-33 cells that have low levels of endogenous Cdc25C protein with
a slow growth rate were transiently transfected with Cdc25C
cDNA in viral DNA vector and cell growth was analyzed by
counting cell numbers. Fig. 4A showed that the growth of Cdc25C
cDNA-transfected C-33 cells was increased by about 80% in
average (p,0.05). Western blot analyses validated that Cdc25C
and Cyclin B1, but not Cyclin D1 protein levels, were elevated in
Cdc25C cDNA-transfected cells, approximately 9- and 4-fold of
that in control cells transfected with vector alone semi-quantified
by densitometric analyses followed by normalizing to control cells
(Fig. 4A, right panel).
To validate the role of Cdc25C in up-regulating PCa cell
growth, we analyzed the effect of down-regulation of Cdc25C
protein by shRNA. Transient knock-down of Cdc25C protein by
shRNA in AS LNCaP C-33 in SR condition (Fig. 4B, left panel,
column #3 vs. #1) and AI PC-3 cells in regular medium (Fig. 4C,
left panel) resulted in approximately an average of 35% decrease
of cell proliferation (p,0.05). Western blot analyses revealed that
Cdc25C proteins were mostly reduced in shRNA-transfected C-33
and PC-3 cells (Fig. 4B, right panel, lane #3 vs. #1 & Fig. 4C,
right panel). In those cells, Cdc25A and Cdc25B protein levels
were not changed, indicating the specificity of the shRNA to
Cdc25C (Figs. 4B and 4C). In Cdc25C knock-down cells, Cyclin
B1 protein levels were concurrently decreased by 60% in C-33
cells in SR condition (Fig. 4B, right panel, lane #3 vs. #1) and
over 90% in PC-3 cells (Fig. 4C, right panel). Interestingly, the
Cyclin D1 protein level was not much changed in either Cdc25C
cDNA-transfected or shRNA-transfected C-33 cells (Figs. 4A &
4B) and was reduced by about 65% in PC-3 cells (Fig. 4C).
We further determined the effect of the knockdown of Cdc25C
on DHT-stimulated C-33 cell proliferation. As shown in Fig. 4B
(left panel, column #4 vs. #3), androgens could not significantly
stimulate the growth of Cdc25C-shRNA transfected C-33 cells,
despite the fact that DHT partially restored both Cdc25C and
Cyclin B1 protein levels (Fig. 4B, right panel, lane #4 vs. #3). In
comparison, DHT significantly increased the growth of control
cells transfected with vector alone by over 40% of the mean of cell
number (Fig. 4B, left panel, column #2 vs. #1, *p,0.05). The
data collectively support the notion that Cdc25C protein plays a
4
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Figure 2. Effects of androgens on Cdc25C and cell cycle protein levels in PCa cells. (A) LNCaP C-33 and C-81 cells were seeded at a density
of 86103 and 66103 cells/cm2, respectively, in duplicates for 3 days in regular medium. Cells were steroid-starved for 48 hr in SR medium and then
treated with 10 nM DHT for 24 hr and 48 hr. Total cell lysate proteins were harvested and analyzed for Cdc25C, Cdc25B, cPAcP, Cyclin B1 and Cyclin
D1 proteins. b-actin was detected for serving as a loading control. (B) AS LNCaP C-33 and (C) VCaP cells were plated at a density of 86103 and 26104
cells/cm2, respectively, for 3 days, and then steroid starved for 48 hr in SR medium. Cells were treated with 10 nM DHT with or without 10 mM
Casodex for 48 hr. (B) For C-33 cells, total cell lysate proteins were analyzed for AR, Cdc25A, Cdc25B, Cdc25C, cPAcP, PSA, Cyclin D1 and Cyclin B1
protein levels. (C) For VCaP cells, total cell lysate proteins were analyzed for AR, Cdc25C, Cyclin D1, Cyclin B1 and PSA protein levels. b-actin was
analyzed in each experiment and used as a loading control. (D) Effect of DHT vs. EGF on Cdc25C protein level in C-33 cells. Steroid-starved C-33 cells
were treated with 10 nM DHT or 10 ng/ml EGF for 24 hr, and control cells were treated with solvent alone. All cells were harvested for analyzing
Cdc25C protein level. As controls, cPAcP, ErbB-2 and its tyrosine phosphorylation at Y877, AR and its phosphorylation at S81, and Cyclin B1 were also
analyzed. Tubulin was detected for serving as a loading control.
doi:10.1371/journal.pone.0061934.g002

(Fig. 5A, lane #4); while CHX can effectively block DHT-induced
PSA, an androgen-regulated protein (Fig. 5A, lane #6). Thus, the
data indicated that in DHT-treated cells, the elevation of Cdc25C
protein level could not be explained by de novo biosynthesis alone.

critical role in regulating the basal as well as the androgenstimulated proliferation of PCa cells.

Effects of de novo biosynthesis inhibitors on Cdc25C
protein level by androgens

Effect of inhibitors of proteasomal and lysosomal
degradation pathways on Cdc25C protein levels

We investigated the mechanism that androgens upregulate the
Cdc25C protein level by analyzing if DHT increases Cdc25C
protein biosynthesis. In LNCaP C-33 cells, in the absence of
androgens, the basal Cdc25C protein level was further reduced by
Act D and CHX treatments, inhibitors of de novo RNA synthesis
and de novo protein synthesis, respectively (Fig. 5A, lanes #3 & #5
vs. #1). In the presence of DHT, Act D and CHX only had a
partial effect on decreasing DHT-induced Cdc25C protein levels
in these cells (Fig. 5A, lane #4 & #6 vs. #2). As controls, Act D
only partially blocked DHT effects on AR and PSA protein levels
PLOS ONE | www.plosone.org

We investigated the involvement of protein degradation
pathways in up-regulating Cdc25C protein by DHT. Cdc25C
protein was analyzed in C-33 cells treated with proteasomal
inhibitors MG 132 (0.01, 0.05 and 0.1 mM) and epoximicin (0.1
and 1.0 mM). DHT effect on Cdc25C protein level was used as the
positive control. As shown in Fig. 5B, in MG132-treated C-33
cells, Cdc25C protein level was elevated, following a dose-response
fashion, although to a lesser degree than DHT effect. Epoximicin
5
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Figure 3. Androgen effects on the cell cycle of LNCaP C-33 cells. AS LNCaP C-33 cells were seeded at a density of 26104 cells/cm2 in regular
medium for 3 days followed by maintaining in SR medium for 2 days. Cells were then fed with fresh SR medium and treated with 10 nM DHT or
solvent alone as control cells. (A & B) One set of cells were harvested at 24 hr treatment, and (C & D) another set of cells were harvested upon 48 hrtreatment for analyzing cell cycle distribution by Flow cytometry analyses.
doi:10.1371/journal.pone.0061934.g003

treatments also caused an increase of Cdc25C protein level with a
more potent effect than DHT, following a dosage-response fashion
(Fig. 5C). Interestingly, in DHT-treated cells, an additional
Cdc25C band with a slightly slower mobility appeared, which is
possibly due to phosphorylation (Fig. 5B). The data indicate that
DHT up-regulation of the Cdc25C protein level could be in part
via inhibiting the proteasomal degradation pathway.
Since ubiquitination signals proteasomal degradation, we
investigated DHT effect on the ubiquitination of Cdc25C protein
in DHT-treated LNCaP C-33 cells vs. control cells treated with the
solvent alone. The total cell lysate proteins were immunoprecipitated with anti-Cdc25C Ab, and the immunocomplexes were
analyzed by immunoblotting with anti-Cdc25C Ab (Fig. 5D, left
panel) and anti-ubiquitin Ab (Fig. 5D, right panel), respectively. As
shown in Fig. 5D (left panel, lane #3), in the absence of DHT,
PLOS ONE | www.plosone.org

Cdc25C protein was highly ubiquitinated as indicated by the
appearance of high molecular mass complexes by anti-Cdc25C
Ab. The ubiquitinated Cdc25C protein complexes were greatly
decreased in DHT-treated LNCaP C-33 cells (Fig. 5D, left panel,
lane #4 vs. #3). Similarly, the ubiquitinated proteins by antiubiquitin Ab were decreased in DHT-treated C-33 cells (Fig. 5D,
right panel, lane #4 vs. #3) despite an additional band was
detected (Complex Ib in Fig. 5D, right panel, lane #3). Together
these results support the notion that androgens reduce the
degradation of Cdc25C in part by inhibiting its ubiquitination
and elevated Cdc25C protein levels correlate with increased cell
proliferation.
We also analyzed the effects of lysosomal protease inhibitors
leupeptin (10 to 200 mM) and E64D (0.01 to 1.0 mM) on Cdc25C
protein levels. Unexpectedly, the Cdc25C protein level was
6
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Figure 4. Effect of Cdc25C protein expression on the proliferation of PCa cells. (A,B) LNCaP C-33 and (C) PC-3 cells were plated at a density
of 1.26104 or 16104 cells/cm2 for 72 hr and then transfected with Cdc25C cDNA (A) or shRNA (B,C) plasmids. Control cells were transfected with the
respective vector alone. (A) Cdc25C cDNA transfected C-33 cells were cultured in regular medium and the cell number was then counted after 2 days.
(B) Cdc25C shRNA-transfected C-33 cells were steroid starved for 48 hr in SR medium, and then treated with or without 10 nM DHT for 2 days. (C)
Cdc25C shRNA transfected PC-3 cells were cultured in regular medium for 2 days, and the cell number was counted. The ratio of cell proliferation was
calculated by normalizing the experimental cell number to that of control cells transfected with vector alone, respectively. Total cell lysate proteins
were analyzed for Cdc25A, Cdc25B, Cdc25C, Cyclin B1 and/or Cyclin D1 proteins. b-actin was used as a loading control. The ratios of Cdc25C, Cyclin B1
and CyclinD1 protein levels to b-actin were calculated after semi-quantification by densitometric analyses on films with different exposure time
periods. *p,0.05, n = 263; Bar, standard deviation.
doi:10.1371/journal.pone.0061934.g004
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Figure 5. Effects of inhibition of protein biosynthesis and degradation pathways on Cdc25C protein levels. (A) Effects of de novo
biosynthesis inhibitors on Cdc25C protein levels by androgens. LNCaP C-33 cells were plated at a density of 1.66104 cells/cm2 for 3 days in regular
medium. Cells were steroid starved for 48 hr in a SR medium, and then treated with 5 mg/mL Actinomycin D (Act D) or 10 mg/mL cycloheximide (CHX)
for 24 hr alone or 10 nM DHT was added 30 min post treatment with Act D and CHX. Total cell lysate proteins were analyzed for Cdc25C, AR and PSA
protein level. b-actin was analyzed as a loading control. (B & C) Effects of inhibitors of proteasomal degradation pathway on Cdc25C protein level.
LNCaP C-33 cells were seeded in regular medium for 72 hr, steroid starved for 48 hr and the cells were treated with or without 10 nM DHT or
different concentrations of proteasomal inhibitors (B) MG132 (0.01, 0.05 and 0.1 mM) and (C) Epoximicin (0.1 and 1.0 M). Cells were harvested and
analyzed for Cdc25C protein levels. b-actin was analyzed serving as a loading control. (D) Effect of androgens on the ubiquitination of Cdc25C
protein. Steroid-starved LNCaP C-33 cells were treated with 10 nM DHT or solvent alone for 48 hr. An aliquot of total cellular lysate proteins was
immunoprecipitated (IP) by reacting with anti-Cdc25C Ab or normal IgG and followed by Protein A-Sepharose beads. The immune complexes were
analyzed by immunoblotting (IB) with anti-Cdc25C Ab (left panel) or anti-ubiquitin Ab (right panel). The positions of ubiquitinated Cdc25C protein
(Ubi-Cdc25C) are indicated by arrows; while an additional band was detected by anti-ubiquitin Ab (Complex Ib). (E & F) Effects of inhibitors of
lysosomal degradation pathway on Cdc25C protein levels. LNCaP C-33 cells were seeded as described in B & C, after steroid starvation, cells were
treated with or without 10 nM DHT or different concentrations of lysosomal protease inhibitors. (E) Leupeptin (10 to 200 mM) and (F) E64D (0.01 to
1.0 mM) for 48 hr. Cells were harvested and analyzed for Cdc25C protein levels. b-actin was analyzed as a loading control.
doi:10.1371/journal.pone.0061934.g005

elevated in leupeptin-treated cells in a dose-dependent manner
(Fig. 5E). Consistently, E64D, another lysosomal protease inhibitor, also elevated Cdc25C protein levels in a dosage-dependent
manner (Fig. 5F). The data thus indicate that DHT-increased
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Cdc25C protein level is at least in part via the inhibition of its
degradation pathways, possibly including both proteasomal and
lysosomal pathways.
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& 4C). The data demonstrated the specificity of shRNA to
Cdc25C. The data also indicate that Cdc25A and B exhibit
unique biological activities in PCa cells, which are not overlapping with that of Cdc25C and unable to cover the loss of
Cdc25C function in promoting the growth of Cdc25C-knockdown
cells. Interestingly, AS MDA PCa2b cells do not express Cdc25C
protein with low Cyclin B1 level and exhibit a very slow growth
rate even in the presence of 20% FBS, while AI DU 145 cells
express Cdc25C and high Cyclin B1 level with rapid cell growth
(data not shown). Furthermore, in Cdc25C cDNA or shRNAtransfected C-33 cells, Cyclin D1 level essentially remained the
same (Fig. 4A & 4B) despite the fact that in PC-3 cells, Cyclin D1 is
decreased by about 65% (Fig. 4C). Thus, Cdc25C signaling in upregulating PCa cell growth is primarily transmitting through
Cyclin B1, but not Cyclin D1.
Our data clearly demonstrate that in AS C-33 cells, DHT
induces the elevation of Cdc25C protein level following a dose(data not shown) and a kinetic-dependent manner (Fig. 2A).
Nevertheless, in AI C-81 cells, 10 nM DHT exhibit an effect on
Cdc25C protein levels by up-to 2-fold (Fig. 2A). Importantly, AR
is required in this mode of regulation in AS C-33 cells (Fig. 2B &
2C). Evidently, when LNCaP C-33 and VCaP cells were
concurrently treated with Casodex, an AR blocker used clinically
in androgen deprivation therapy, DHT is unable to down-regulate
cPAcP (Fig. 2B) or up-regulate the protein level of Cdc25C, Cyclin
B1 or Cyclin D1 (Fig. 2B & 2C). In androgen-treated cells, cPAcP
is down-regulated, which correlates with ErbB-2 and ERK/MAP
kinases activation for promoting PCa cell proliferation (Fig. 2)
[26,27,51]. In parallel, ERK-MAP kinases are shown to be at least
in part involved in regulating Cdc25C during mitotic induction in
ovarian cancer A2780 cells [52]. Furthermore, altered expression
of Cdc25C protein, by cDNA and shRNA transfection, results in
corresponding PCa cell growth regulation (Fig. 4). Thus, in DHTtreated cells, DHT interacts with AR for down-regulating cPAcP,
a negative growth regulator, and up-regulating Cdc25C, a positive
growth regulator; together, key components of the cell cycle
including Cyclin B1 are up-regulated, resulting in promoting PCa
cell proliferation.
Both DHT and EGF function as critical factors in up-regulating
PCa cell proliferation, correlating with decreased cPAcP activity, a
negative growth regulator of PCa cells by functioning as an
authentic PTP (Fig. 2D) [29,44] and activated ErbB-2 tyrosine
phosphorylation signaling (Fig. 2D) [28,51]. In fact, DHTstimulated cell proliferation is in part mediated via ErbB-2
signaling pathway [28,51]. Unexpectedly, only DHT, but not
EGF, can significantly increase Cdc25C protein level in PCa cells,
correlating with cell proliferation (Figs. 2D & 3). Interestingly, we
observed that DHT, but not EGF, can increase a subfraction of
tartrate-insensitive phosphatase activity [44]. Further experiments
should clarify if Cdc25C represents the tartrate-insensitive
phosphatase activity in androgen-stimulated PCa cells, which
may have an important impact on PCa therapy [40,44].
Additionally, while there could be other explanations, the data
imply that DHT and EGF exhibit distinct signal pathways to
stimulate PCa cell proliferation in addition to their cross-talks.
Unexpectedly, we observed broad peaks with the lack of G2
phase by fluorocytometry analyses (Fig. 3). Since those cells were
originally purchased from ATCC and carefully maintained in our
lab for establishing the PCa cell progression model (26,41), the
broad peak may indicate the microheterogeneity nature of cell
culture, including the heterogeneity of aneuploidy in those cells.
Further, the lack of G2 can be due to the delay of S-phase or the
premature mitotic exit. In parallel, it is commonly known that
activation of Cdc25C triggers entry into mitosis and suppress G2/

Discussion
Cdc25 phosphatases play a critical role at the checkpoint for
regulating cell cycle progression by dephosphorylating cyclindependent kinases. Aberrant expression of Cdc25C can lead to
abnormal cell cycle progression, tumor initiation and progression.
For example, increased expression of Cdc25C has been reported
in a fraction of colon cancer cells [45], endometrial cancer [46]
and prostate carcinomas [25]. In prostate carcinomas, Cdc25C
and its spliced forms are upregulated at the mRNA and protein
level [25]. However, the molecular mechanism of its upregulation
in PCa cells remains an enigma. In this communication, our data
clearly show for the first time that Cdc25C protein level is upregulated by androgens in AS PCa cells, at least in part by
decreasing its ubiquitination and degradation. In those cells,
Cdc25C protein levels correlate with the basal as well as the
androgen-stimulated cell proliferation. Furthermore, Cdc25C
protein is elevated in at least a subfraction of AI PCa cells in a
SR condition, and elevated expression of Cdc25C promotes PCa
cell proliferation, which correlates with elevated Cyclin B1 protein
level. Our data provide a mechanistic explanation of elevated
Cdc25C protein levels on clinical prostate carcinomas and its role
in PCa cell proliferation. Our results can have clinical significance
toward advanced PCa therapy including castration-resistant PCa.
In regular culture condition which exhibits androgenic activity
[47], the endogenous Cdc25C protein level, but not Cdc25A or B,
is about 20% lower in AS LNCaP C-33 cells which have a slow
growth rate and low tumorigenicity, than in AI LNCaP C-81 cells
which grow rapidly and are highly tumorigenic, mimicking the
advanced stages of PCa (Fig. 1) [26,28,41]. In SR condition,
among three Cdc25 family members, Cdc25C protein exhibits the
most sensitivity, and its protein level is greatly decreased in AS C33 cells in reference to that in AI C-81 cells (Figs. 1 & 2). In the
same SR-cultured C-33 cells, Cdc25A and Cdc25B proteins are
decreased by only approximately 50% in comparison to the
respective protein level in C-81 cells (Fig. 1). Interestingly, Cdc25B
protein is shown to have over-expression in 97% of human PCa
archival specimens, significantly higher than in non-cancerous
prostate specimens, by immunohistochemistry staining and the
protein level correlates with Gleason scores [48]. In the same
study, Cdc25B is shown to function as a coactivator of AR in a
hormone-dependent manner in LNCaP cells [48]. Despite that,
the function of Cdc25B to AR is independent of its cell cycle
function; Cdc25B is proposed to play a role in human prostate
carcinogenesis [48]. It should be noted that Cdc25B is also shown
to be a cofactor of estrogen receptor [49,50]. While Cdc25B
protein is expressed in all PCa cells examined in our experiments,
our analyses on the expression profile of Cdc25 in cells cultured in
both regular medium and SR condition (Fig. 1) and in the
presence of androgens (Fig. 2A & 2B) show that androgens only
have up-to 2-fold effect on Cdc25B protein level. It is possible that
a 2-fold change in Cdc25B protein is sufficient for regulating its
biological function. It is also possible that Cdc25B protein level is
not directly regulated by androgens despite that it can function as
an AR cofactor in the presence of androgens. Alternatively, in the
PCa cells that were used in our experiments, the regulation of
Cdc25B protein by androgens is altered. Further experiments with
AS normal prostate epithelia are required to address this
possibility. Nevertheless, our data indicate that Cdc25B and
Cdc25C proteins are differentially regulated by androgens in PCa
cells.
Importantly, decreased Cdc25C protein levels by shRNA results
in the growth down-regulation of PCa cells in which Cdc25A and
B protein levels are remained the same as in control cells (Fig. 4B
PLOS ONE | www.plosone.org
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M checkpoint. Over-activation of Cdc25C may override the G2/
M checkpoint and accelerates mitotic entry without proper pre-M
phase activity, for example, DNA repair. This can lead to mitotic
catastrophe because the regulation of mitotic exit also involves in
the inactivation of Cdc25C. Over-activation of Cdc25C can lead
to prolonged mitosis, which thus induces mitotic catastrophe.
Nevertheless, further investigation is required to address androgen
vs. EGF effect on Cdc25C protein involving in PCa cell
proliferation.
Due to the importance of Cdc25C in regulating DHTstimulated PCa cell growth, we elucidate the mechanism that
DHT treatment increases Cdc25C protein. Our results showed
that in the presence of a de novo protein biosynthesis inhibitor alone
in the absence of DHT, the Cdc25C protein level was even lower
than control cells (Fig. 5A, lane #3 & 5 vs. #1); while, an elevated
level was observed when these inhibitors were used with DHT
(Fig. 5A, lane #4 & 6 vs. #1). Thus, upregulation of Cdc25C
could not be explained solely by that DHT up-regulates Cdc25C
expression at the transcriptional level. In parallel, it has been
shown that p53 protein represses Cdc25C expression by directly
binding to the promoter of Cdc25C [53]. Nevertheless, our data
revealed that p53 is not involved in DHT-upregulating Cdc25C
protein in spite of LNCaP expressing the wild type of p53 protein.
Evidently, the p53 protein level is not significantly changed in
DHT-treated cells [54,55] and DHT-induced elevation of
Cdc25C protein is only partially sensitive to protein de novo
biosynthesis inhibitors (Fig. 5A). Therefore, Cdc25C regulation by
androgens, at least in PCa cells, follows a distinct mechanism to
increase its protein level.
Our data show that the Cdc25C protein level is elevated when
LNCaP cells are treated with proteasomal degradation pathway
inhibitors, which is consistent with previous reports (Figs. 5B & 5C)
[56,57]. It is further supported by IP that androgens decrease the
ubiquitination of Cdc25C protein (Fig. 5D). Unexpectedly, our
results further revealed that the Cdc25C protein level is also

elevated in C-33 cells treated by inhibitors toward the lysosomal
protein degradation pathway (Figs. 5E & 5F). The data may
indicate that mono- and poly-ubiquitinated proteins follow
different routes for degradation [58]. Our data also indicate that
androgen-regulating protein stability can be via different degradation pathways [54]. In summary, our data clearly show that in
androgen-treated PCa cells, inhibition of Cdc25C protein
degradation results in its elevated level. Our data further reveal
for the first time that Cdc25C protein can be degraded via both
proteasomal and lysosomal protein degradation pathways.
In summary, our data show for the first time that androgens
stimulate cell growth at least in part through up-regulating
Cdc25C protein by inhibiting its degradation and this promoting
the cell cycle. In PCa cells, Cdc25C, but not Cdc25A or B, plays a
critical role in cell growth regulation. In most of AI PCa cells,
Cdc25C protein level is elevated. In the case of advanced PCa
where cells can produce their own androgens [59] or in AI PCa
cells that do not express AR, it can be beneficial to specifically
inhibit Cdc25C for advanced castration-resistant PCa therapy.
Our data provide new approaches for the development of novel
therapeutics toward advanced stages of prostate cancer.
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